Non-steroidal anti-inflammatory drugs and the risk of psychosis by Laan, W. et al.
  
 University of Groningen
Non-steroidal anti-inflammatory drugs and the risk of psychosis





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2007
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Laan, W., Selten, J-P., Grobbee, D. E., Smeets, H., Kahn, R. S., & Burger, H. (2007). Non-steroidal anti-
inflammatory drugs and the risk of psychosis. European Neuropsychopharmacology, 17(4), 309-311.
https://doi.org/10.1016/j.euroneuro.2006.09.003
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
www.e l sev i e r. com/ loca te /eu roneu ro
European Neuropsychopharmacology (2007) 17, 309–311SHORT COMMUNICATION
Non-steroidal anti-inflammatory drugs and the
risk of psychosis
W. Laana,⁎, Jean-Paul Seltenb, D.E. Grobbeea, H. Smeets c,
René S. Kahnb, Huibert Burgera,d,ea Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
b Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht,
Utrecht, The Netherlands
c Agis Health Insurance
d Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands
e Department of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands
Received 27 June 2006; received in revised form 5 September 2006; accepted 22 September 2006⁎ Corresponding author. Julius Cent
Primary Care, University Medical Cen
3508 GA, Utrecht, The Netherlands. Te
30 250 5480.
E-mail address: W.Laan@umcutrech
0924-977X/$ - see front matter © 200
doi:10.1016/j.euroneuro.2006.09.003Abstract The objective of the current research was to examine the relation between non-
steroidal anti-inflammatory drugs (NSAID) use and risk of psychosis. To this end we performed a
longitudinal case-control study using prescription data from a Dutch health insurance company.
Men aged 25 years or over and women aged 30 years or over were excluded to prevent inclusion of
non-incident cases. This resulted in eighty-two cases and 359 randomly selected controls from
the same population. The overall relative risk of incident antipsychotic use for NSAID users,
adjusted for age and prescription frequency, was 0.80 (95% CI: 0.48–1.33). After stratification for
gender the risk of psychosis was significantly lower (59%) in male NSAID users only. The relative
risks for male and female subjects were 0.41 (95% CI: 0.17–0.97) and 1.31 (95% CI: 0.65–2.64),
respectively. These results suggest that in men NSAIDs may lower the risk of psychosis.





A negative association between the occurrence of rheumatoid
arthritis and schizophrenia has been known for a long time
(Mors et al., 1999). This suggests involvement of the immune
system in the pathophysiology of schizophrenia. Indeed,
immune alterations have been observed in patients wither for Health Sciences and
ter Utrecht, PO Box 85500,
l.: +31 30 253 8644; fax: +31
t.nl (W. Laan).
6 Elsevier B.V. and ECNP. All rightschizophrenia (Cazzullo et al., 2001; Korschenhausen et al.,
1996; Maes et al., 1995; Naudin et al., 1997; Schwarz et al.,
2001), although it cannot be excluded that these changes
result from long-term neuroleptic treatment (DeLisi, 1996).
Some of the immunological changes may be counteracted by
prostaglandin inhibitors, e.g. non-steroidal anti-inflammatory
drugs (NSAIDs). Muller et al. (2002) showed a beneficial effect
of add-on therapy with celecoxib. Improved understanding of
the putative relation between NSAID use and risk of psychosis
may shed a light on the immunological inflammation hypoth-
esis and may point at new treatment options.
The present study aims to longitudinally investigate the
relation between NSAID use and subsequent schizophrenics reserved.
Table 1 Relative risk of psychosis according to NSAID use (with 95% confidence interval), for the group as a whole and for men and
women separately
Unadjusted Adjusted for age Adjusted for age and prescription frequency
Men 0.58 (0.26–1.31) 0.44 (0.19–1.05) 0.41 (0.17–0.97)
Women 1.47 (0.78–2.90) 1.47 (0.74–2.90) 1.31 (0.65–2.64)
Total 0.87 (0.53–1.42) 0.85 (0.51–1.40) 0.80 (0.48–1.33)
310 W. Laan et al.psychosis. The relation was additionally studied in men and
women separately because males are at a considerably
higher psychosis risk than females (Aleman et al., 2003), and
because the negative association with rheumatoid arthritis
has shown to be modified by gender (Mors et al., 1999).
2. Experimental procedures
We performed a prospective nested case-control analysis using
anonymized pharmacy records from the Agis Health Insurance
Database (N=550,000). Data on all prescribed NSAIDs (ATC-codes
N02BA (01-to-79) and M01A (A01-to-X68) and anti-psychotics (ATC-
code N05A (A01-to-X12) between 1995 and 2002 were extracted.
All study subjects were registered at the insurance company for
at least 5 years. Cases were those insured with first use of anti-
psychotics during at least 3 months in the years 2000 to 2002. To
prevent inclusion of non-incident cases, men aged 25 years or over
and women aged 30 years or over were excluded. These age cut-offs
correspond to the respective mean ages of disease onset (Hafner,
2003). Controls were a random, four times larger sample of non-
cases from the same database. We took account of prescription
frequency of any medication because cases who were socially
withdrawing before disease onset may have been less likely to visit a
general practitioner and consequently, to receive any medication,
including an NSAID.
For cases, NSAID use and prescription frequency were defined as
any prescription for NSAIDs and total number of prescriptions per
year in the 4 years preceding anti-psychotics use. For controls this
period was defined by calendar years 1999 to 2002. Subjects using
lithium suggesting bipolar disorder, or methotrexate or sulfasalazine
suggesting rheumatoid arthritis, were excluded. We calculated odds
ratios (OR) with 95% confidence intervals (95% CI) as measures of
relative risk of NSAID use for psychosis.
Using logistic regression additional adjustments were made for
age and prescription frequency. We repeated the analyses while
stratifying for gender.
3. Results
Eighty-two cases and359 controlswere included in the analysis.
Cases showed the same mean age as controls (21 years) but a
higher proportion of males (52 versus 30%) and a higher mean
prescription frequency (6.5 versus 4.8/year). The four-year
cumulative incidence of NSAID use in the source population, as
estimated from the controls, was 41% (95% CI 36–46%). Among
NSAID usersmean agewas 22 years (range 13 to 30) and 26%was
male. For non-NSAID users mean age was 20 years (range 12 to
30) and 40% was male. Mean age for males was 19 years and
22 years for females.
Overall, the relative risk of psychosis for NSAID users was
0.87 (95% CI: 0.53–1.42). After adjustment for age and
prescription frequency the relative risk was similar, i.e. 0.80
(95% CI: 0.48–1.33). Further analyses were stratified for
gender (Table 1). NSAID use was significantly related to a 59%decreased risk of psychosis in men (adjusted relative risk
0.41 (95% CI: 0.17–0.97)) while in women, NSAID use was
associated with a small and statistically non-significant
increase in risk (1.31 (95% CI: 0.65–2.64)). The two-tailed
p-value for interaction between gender and NSAID use was
0.08.
4. Discussion
The results of the present study show a protective effect of
NSAIDs on the risk for treated psychosis in men only.
To appreciate this finding, some characteristics of the
study need to be addressed. The incident use of anti-
psychotics was used in this analysis as a proxy for incident
psychosis. In both a Dutch and an Italian study (Barbui et
al., 2004; Rijcken et al., 2003) a substantial part of anti-
psychotics were prescribed for other indications, notably
non-schizophrenic psychosis. This could have resulted in a
slight overestimation of the true incidence of schizophrenic
psychosis. As it is highly unlikely that this overestimation
has selectively affected NSAID users, the consequent
misclassification has been non-differential, with underesti-
mation of the observed effect as a result. Another potential
limitation of the data is that prescription data may not
completely cover NSAID use in the population. In the
Netherlands certain NSAIDs can be without prescription,
i.e. over the counter. Consequently insurance companies
will not register these NSAIDs, leading to an underestima-
tion of true NSAID use. If subjects in the prodromal phase of
psychosis were more likely to omit a visit to their general
practitioner than healthy subjects and consequently per-
haps used more over the counter NSAIDS instead, overes-
timation of the protective effect may have occurred. To
antagonize this potential bias we controlled in the analyses
for prescription frequency for any medication. Yet, overall
prescription frequency may not fully capture the tendency
of cases to visit their GP.
Our findings agree with previous reports from the limited
number of studies carried out in this area. In a case report
review by Jiang and Chang (1999) 5 cases with adverse
psychiatric reactions to NSAIDs are described. This suggests
that the use of NSAIDs at least may have an effect on the
central nervous system. As far as we know only one study
addressed the effect of NSAIDS on psychosis directly. In this
study, a randomized trial by Muller (Muller et al., 2002) 25
male and 25 female patients with acute exacerbation of
schizophrenia were randomly assigned to either risperidone
plus celecoxib (COX-2 NSAID), or risperidone plus placebo.
The celecoxib group showed significantly greater improve-
ment in total PANSS (Positive and Negative Syndrome Scale)
scores indicating that the addition of NSAIDs to regular anti-
psychotic treatment may have beneficial effects on the
311Non-steroidal anti-inflammatory drugs and the risk of psychosiscourse of schizophrenia. Unfortunately, no gender-specific
results were presented.
A possible effect of NSAIDs on the occurrence and course
of psychosis is plausible in view of a number of mechanisms
proposed in the literature.
Psychotic symptoms have been described in processes
accompanied by a process of inflammation and in several
autoimmune disorders involving the CNS (Chong et al., 2003;
Hanson and Gottesman, 2005; Muller et al., 2004). Signs of
inflammation were found in the post-mortem CNS tissues of
some schizophrenic patients (Korschenhausen et al., 1996)
Recently, it has been discovered that the cyclo-oxygenase
enzyme in platelets, which is inhibited by NSAIDs, is
hyperactive in schizophrenia (Das and Khan, 1998). The
observations of our study suggest that the use of NSAIDs
might reduce the risk of schizophrenia in males only. An
explanation for the absence of a positive effect of NSAIDS in
women may be that the supposed protection by estrogens
(Riecher-Rössler, 2002) leaves little room for positive effects
of NSAIDs.
In conclusion, our findings in a large cohort study with
over 80 patients with incident treated psychosis support the
view that NSAIDs may reduce the risk of future psychosis,
although this effect appears to be restricted to males.
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